A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

被引：0
|
作者：
Chi, K. N.
Beardsley, E. K.
Venner, P. M.
Eigl, B. J.
Hotte, S. J.
Ko, Y.
Saad, F.
Winquist, E.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Juravinski Canc Ctr, Hamilton, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] London Hlth Sci Ctr, London, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5166
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE 2 STUDY OF PATUPILONE IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (HRPC) WHO HAVE PROGRESSED AFTER DOCETAXEL
    Chi, K. N.
    Beardsley, E.
    Eigl, B.
    Venner, P.
    Hotte, S. J.
    Winquist, E.
    Ko, Y. J.
    Saad, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 189 - 189
  • [2] A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel
    Beardsley, E. K.
    Saad, F.
    Eigl, B.
    Venner, P.
    Hotte, S.
    Winquist, E.
    Ko, Y. J.
    Sridhar, S. S.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] An open label randomized Phase II study of oral triple angiokinase inhibitor BIBF 1120 in Hormone Refractory Prostate Cancer (HRPC) patients who progressed after docetaxel
    Oudard, S.
    Chevreau, C.
    Flechon, A.
    Gunzer, K.
    Houede, N.
    Krakowski, I.
    de Mont-Serrat, H.
    Rouyrre, N.
    Kaiser, R.
    Droz, J. P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 280 - 280
  • [4] A phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC)
    George, DJ
    Gockerman, JP
    Petros, W
    Haley, S
    Franklin, AD
    Creel, PA
    Turner, AG
    Sleep, D
    Hurwitz, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 419S - 419S
  • [5] A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    Breitz, H. B.
    Roman, L. A.
    Karlov, P. A.
    Cheporov, S. V.
    Lopatkin, N. D.
    Baker, G. S.
    Karlin, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy.
    Tay, MH
    George, DJ
    Gilligan, TD
    Kelly, SM
    Appleby, L
    Taplin, ME
    Febbo, PG
    Kantoff, PW
    Oh, WK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 426S - 426S
  • [7] Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    DeJager, R.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H. B.
    Earhart, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [8] Phase II study of FK228 in patients with metastatic hormone refractory prostate cancer (HRPC)
    Molife, Rhoda
    Dearnaley, David
    Parker, Chris
    Patterson, Stephen
    Riggs, Charles
    Higano, Celestia
    Stadler, William M.
    McCulloch, William
    Shalaurov, Alex
    de Bono, Johann
    ANNALS OF ONCOLOGY, 2006, 17 : 149 - 149
  • [9] A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Eigl, B. J.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I/II study of weekly docetaxel and vinblastine in the treatment of hormone-refractory prostate cancer (HRPC).
    Ackler, JR
    Tester, WJ
    Leighton, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 771S - 771S
12345